Krystal Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Krystal Biotech
KRYS Stock  USD 188.50  1.61  0.86%   
Krystal Biotech financial statements provide useful quarterly and yearly information to potential Krystal Biotech investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Krystal Biotech financial statements helps investors assess Krystal Biotech's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Krystal Biotech's valuation are summarized below:
Gross Profit
270.5 M
Profit Margin
0.3069
Market Capitalization
5.4 B
Enterprise Value Revenue
16.4994
Revenue
290.5 M
There are over one hundred nineteen available fundamental ratios for Krystal Biotech, which can be analyzed over time and compared to other ratios. All traders should check Krystal Biotech's last-minute fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 3.2 B in 2025. Enterprise Value is likely to gain to about 2.9 B in 2025

Krystal Biotech Total Revenue

305.04 Million

Check Krystal Biotech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Krystal Biotech's main balance sheet or income statement drivers, such as Net Interest Income of 31.1 M, Interest Income of 31.1 M or Depreciation And Amortization of 7 M, as well as many indicators such as Price To Sales Ratio of 14.65, Dividend Yield of 0.0 or PTB Ratio of 4.5. Krystal financial statements analysis is a perfect complement when working with Krystal Biotech Valuation or Volatility modules.
  
Check out the analysis of Krystal Biotech Correlation against competitors.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Krystal Biotech Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets1.1 B1.1 B304.3 M
Slightly volatile
Short and Long Term Debt Total7.7 M7.3 M4.6 M
Slightly volatile
Total Current Liabilities107.1 M102 M19.9 M
Slightly volatile
Total Stockholder Equity993.7 M946.4 M280.9 M
Slightly volatile
Other Liabilities355 K338.1 K175 K
Slightly volatile
Property Plant And Equipment Net81.6 M161.4 M46.8 M
Slightly volatile
Accounts Payable2.8 M5 M1.6 M
Slightly volatile
Cash222.1 M344.9 M128.2 M
Slightly volatile
Non Current Assets Total329.5 M313.8 M80.3 M
Slightly volatile
Cash And Short Term Investments314.7 M597.5 M181.3 M
Slightly volatile
Common Stock Shares Outstanding19.6 M29.7 M12.9 M
Slightly volatile
Long Term Debt Total1.5 M1.7 M1.8 M
Slightly volatile
Liabilities And Stockholders Equity1.1 B1.1 B304.3 M
Slightly volatile
Capital Surpluse886.9 M844.7 M295.8 M
Slightly volatile
Other Current Assets13.9 M13.3 M3.7 M
Slightly volatile
Other Stockholder Equity1.2 B1.1 B348.6 M
Slightly volatile
Total Liabilities114.9 M109.5 M23.4 M
Slightly volatile
Property Plant And Equipment Gross192.5 M183.4 M56.6 M
Slightly volatile
Total Current Assets779.1 M742 M224 M
Slightly volatile
Property Plant Equipment204.9 M195.2 M56.5 M
Slightly volatile
Net Invested Capital481 M946.4 M270.4 M
Slightly volatile
Net Working Capital354.4 M640 M204.8 M
Slightly volatile
Capital Lease Obligations8.6 M7.3 M5.3 M
Slightly volatile

Krystal Biotech Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Interest Income31.1 M29.7 M6.1 M
Slightly volatile
Depreciation And Amortization7 M6.7 M1.8 M
Slightly volatile
Selling General Administrative119.4 M113.7 M30 M
Slightly volatile
Other Operating Expenses236.1 M224.8 M54.8 M
Slightly volatile
Research Development56.3 M53.6 M17.3 M
Slightly volatile
Total Operating Expenses215 M204.8 M52.8 M
Slightly volatile
Reconciled Depreciation7 M6.7 M1.8 M
Slightly volatile

Krystal Biotech Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Sale Purchase Of Stock429.4 M409 M141.5 M
Slightly volatile
Net Borrowings2.3 M2.6 M2.1 M
Slightly volatile
Stock Based Compensation51.6 M49.1 M12.2 M
Slightly volatile
Depreciation7 M6.7 M1.8 M
Slightly volatile
Capital Expenditures4 M4.2 M10.3 M
Slightly volatile
Total Cash From Financing Activities25.7 M27 M63.3 M
Slightly volatile
End Period Cash Flow222.1 M344.9 M128.2 M
Slightly volatile
Change To Netincome39.3 M37.4 M10.5 M
Slightly volatile
Begin Period Cash Flow202.5 M358.3 M105.5 M
Slightly volatile
Cash And Cash Equivalents Changes78.4 M83.9 M63.2 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio14.6515.4182150
Slightly volatile
PTB Ratio4.54.73370.8307
Slightly volatile
Days Sales Outstanding239132288
Slightly volatile
Book Value Per Share34.7533.099511.9918
Slightly volatile
Average Payables2.5 M3.4 M2.9 M
Very volatile
Stock Based Compensation To Revenue0.160.16910.7005
Slightly volatile
Capex To Depreciation0.60.63128.4612
Very volatile
PB Ratio4.54.73370.8307
Slightly volatile
EV To Sales13.5414.256191.0689
Slightly volatile
Inventory Turnover0.480.75680.4649
Slightly volatile
Days Of Inventory On Hand718482796
Slightly volatile
Payables Turnover4.234.02430.882
Slightly volatile
Sales General And Administrative To Revenue3.243.643.97
Slightly volatile
Research And Ddevelopement To Revenue0.180.18444.5598
Slightly volatile
Capex To Revenue0.01390.01461.2981
Slightly volatile
Cash Per Share10.7920.8988.4308
Slightly volatile
Days Payables Outstanding86.1690.69961.8 K
Slightly volatile
Current Ratio6.917.275338.3496
Slightly volatile
Tangible Book Value Per Share34.7533.099511.9918
Slightly volatile
Receivables Turnover1.592.77351.3279
Slightly volatile
Graham Number25.7248.190618.7214
Slightly volatile
Shareholders Equity Per Share34.7533.099511.9918
Slightly volatile
Debt To Equity0.00730.00772.799
Slightly volatile
Capex Per Share0.140.14820.4585
Slightly volatile
Graham Net Net10.2720.28097.8643
Slightly volatile
Revenue Per Share10.6710.16071.9369
Slightly volatile
Interest Debt Per Share0.430.2540.4058
Pretty Stable
Debt To Assets0.00650.00690.378
Slightly volatile
Operating Cycle9576141.1 K
Slightly volatile
Price Book Value Ratio4.54.73370.8307
Slightly volatile
Days Of Payables Outstanding86.1690.69961.8 K
Slightly volatile
Company Equity Multiplier1.951.11573.9516
Slightly volatile
Long Term Debt To Capitalization0.690.780.8483
Slightly volatile
Total Debt To Capitalization0.00720.00760.387
Slightly volatile
Debt Equity Ratio0.00730.00772.799
Slightly volatile
Quick Ratio6.667.015438.3045
Slightly volatile
Net Income Per E B T0.710.9350.8445
Pretty Stable
Cash Ratio3.213.381233.78
Slightly volatile
Days Of Inventory Outstanding718482796
Slightly volatile
Days Of Sales Outstanding239132288
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.090.96571.2139
Slightly volatile
Price To Book Ratio4.54.73370.8307
Slightly volatile
Fixed Asset Turnover1.891.79940.5164
Slightly volatile
Debt Ratio0.00650.00690.378
Slightly volatile
Price Sales Ratio14.6515.4182150
Slightly volatile
Asset Turnover0.290.27520.0597
Slightly volatile
Gross Profit Margin0.730.93090.8825
Pretty Stable
Price Fair Value4.54.73370.8307
Slightly volatile

Krystal Biotech Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.2 B3 B1 B
Slightly volatile
Enterprise Value2.9 B2.7 B877.7 M
Slightly volatile

Krystal Fundamental Market Drivers

Forward Price Earnings24.8756
Cash And Short Term Investments597.5 M

Krystal Upcoming Events

26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Krystal Biotech Financial Statements

Krystal Biotech shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Krystal Biotech investors may analyze each financial statement separately, they are all interrelated. The changes in Krystal Biotech's assets and liabilities, for example, are also reflected in the revenues and expenses on on Krystal Biotech's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-2.1 M-2 M
Total Revenue290.5 M305 M
Cost Of Revenue20.1 M21.1 M
Stock Based Compensation To Revenue 0.17  0.16 
Sales General And Administrative To Revenue 3.64  3.24 
Research And Ddevelopement To Revenue 0.18  0.18 
Capex To Revenue 0.01  0.01 
Revenue Per Share 10.16  10.67 
Ebit Per Revenue 0.23  0.24 

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY